thalidomide has been researched along with Animal Mammary Carcinoma in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide." | 5.43 | Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. ( Amorim, RL; Camargo Nunes, F; Carneiro, RA; Cassali, GD; de Campos, CB; Fialho Ligório, S; Lavalle, GE, 2016) |
| "The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide." | 1.43 | Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. ( Amorim, RL; Camargo Nunes, F; Carneiro, RA; Cassali, GD; de Campos, CB; Fialho Ligório, S; Lavalle, GE, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zduniak, K | 1 |
| Gdesz-Birula, K | 1 |
| Woźniak, M | 1 |
| Duś-Szachniewicz, K | 1 |
| Ziółkowski, P | 1 |
| Rossi, F | 1 |
| Sabattini, S | 1 |
| Vascellari, M | 1 |
| Marconato, L | 1 |
| de Campos, CB | 1 |
| Lavalle, GE | 1 |
| Fialho Ligório, S | 1 |
| Camargo Nunes, F | 1 |
| Carneiro, RA | 1 |
| Amorim, RL | 1 |
| Cassali, GD | 1 |
3 other studies available for thalidomide and Animal Mammary Carcinoma
| Article | Year |
|---|---|
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Endothe | 2020 |
The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dog Diseases; Dogs; Drug Therapy, Combina | 2018 |
Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, | 2016 |